Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Review Article
Therapeutic Targets for Diabetes Mellitus: An Update
| Nivedita Tiwari, Ajit Kumar Thakur, Vinay Kumar, Amitabha Dey and Vikas Kumar* | |
| Department of Pharmaceutics, Neuropharmacology Research Laboratory, Indian Institute of Technology (Banaras Hindu University), Varanasi, India | |
| Corresponding Author : | Vikas Kumar Neuropharmacology Research Laboratory, Department of Pharmaceutics Indian Institute of Technology (Banaras Hindu University) Varanasi-221 005, India Tel: +91-542-6702742 Fax: +91-542-2368428 E-mail: vikas.phe@iitbhu.ac.in |
| Received March 17, 2014; Accepted May 13, 2014; Published May 15, 2014 | |
| Citation: Tiwari N, Thakur AK, Kumar V, Dey A, Kumar V (2014) Therapeutic Targets for Diabetes Mellitus: An Update. Clin Pharmacol Biopharm 3:117. doi:10.4172/2167-065X.1000117 | |
| Copyright: © 2014 Tiwari N et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Diabetes mellitus is a common form of metabolic disorder where level of blood glucose in the bloodstream raises high, because of deficiency of insulin and development of insulin resistance in diabetic individuals. It is categorize under modern age life style disorder, commonly affected by middle-aged people and the children in adolescents in most developed countries. Diabetic patients develop serious complication with the development of disease, such as obesity, risk of stroke and heart failure. The worldwide prevalence of diabetes is likely to increase from 382 million people in 2013 to 592 million by 2035. Globally antidiabetic drugs formulate the second-largest market by sales in the pharmaceuticals industry after cancer. Various novel targets have identified and recently various therapeutic leads successfully completed their different phases of clinical trials such as GLP-1 agonist, DPP-IV inhibitors, SGLT2 inhibitors, and are going to be the next generation therapy for management of diabetes. Presently the information was collects from PubMed, Science Direct, SciFinder and Google Scholar. In this review, we spotlighted on some common therapeutic targets involved in type 2 diabetes, offering a new concept for developing new drug candidates to produce newer generation antidiabetic drugs against type 2 diabetes.
